연구동향 분석

암 면역 치료의 최신 지견

정만기 김보영 2015년

논문상세정보
인용/피인용
' 암 면역 치료의 최신 지견' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 치과의학, 이비인후과학, 안과학
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
2,218 1

0.0%

' 암 면역 치료의 최신 지견' 의 참고문헌

  • Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
    Qureshi OS Science 332 (6029) : 600 ~ 603 [2011]
  • Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
    Qureshi OS Science 332 6029 600-603 [2011]
  • The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck
    Strauss L Clin Cancer Res 13 (21) : 6301 ~ 6311 [2007]
  • The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck
    Strauss L Clin Cancer Res 13 21 6301-6311 [2007]
  • The abscopal effect associated with a systemic anti-melanoma immune response
    Stamell EF Int J Radiat Oncol Biol Phys 85 (2) : 293 ~ 295 [2013]
  • The abscopal effect associated with a systemic anti-melanoma immune response
    Stamell EF Int J Radiat Oncol Biol Phys 85 2 293-295 [2013]
  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    Topalian SL N Engl J Med 366 (26) : 2443 ~ 2454 [2012]
  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    Topalian SL N Engl J Med 366 26 2443-2454 [2012]
  • Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
    Hamid O N Engl J Med 369 (2) : 134 ~ 144 [2013]
  • Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
    Hamid O N Engl J Med 369 2 134-144 [2013]
  • Reversal of the TCR stop signal by CTLA-4
    Schneider H Science 313 (5795) : 1972 ~ 1975 [2006]
  • Reversal of the TCR stop signal by CTLA-4
    Schneider H Science 313 5795 1972-1975 [2006]
  • Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma
    Cho YA Oral Oncol 47 (12) : 1148 ~ 1153 [2011]
  • Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma
    Cho YA Oral Oncol 47 12 1148-1153 [2011]
  • Regulation of the steps of angiogenesis by human head and neck squamous cell carcinomas
    Benefield J Invasion Metastasis 16 (6) : 291 ~ 301 [1996]
  • Regulation of the steps of angiogenesis by human head and neck squamous cell carcinomas
    Benefield J Invasion Metastasis 16 6 291-301 [1996]
  • Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
    Gabrilovich DI Nat Med 2 (10) : 1096 ~ 1103 [1996]
  • Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
    Gabrilovich DI Nat Med 2 10 1096-1103 [1996]
  • Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma
    Chi KH Oncology 60 (2) : 110 ~ 115 [2001]
  • Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma
    Chi KH Oncology 60 2 110-115 [2001]
  • Phase I/II trial of tremelimumab in patients with metastatic melanoma
    Camacho LH J Clin Oncol 27 (7) : 1075 ~ 1081 [2009]
  • Phase I/II trial of tremelimumab in patients with metastatic melanoma
    Camacho LH J Clin Oncol 27 7 1075-1081 [2009]
  • Phase I dendritic cell p53 peptide vaccine for head and neck cancer
    Schuler PJ Clin Cancer Res 20 (9) : 2433 ~ 2444 [2014]
  • Phase I dendritic cell p53 peptide vaccine for head and neck cancer
    Schuler PJ Clin Cancer Res 20 9 2433-2444 [2014]
  • PD-L1 expression on tolerogenic APCs is controlled by STAT-3
    Wölfle SJ Eur J Immunol 41 (2) : 413 ~ 424 [2011]
  • PD-L1 expression on tolerogenic APCs is controlled by STAT-3
    Wölfle SJ Eur J Immunol 41 2 413-424 [2011]
  • Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer
    Wolf GT Head Neck 33 (12) : 1666 ~ 1674 [2011]
  • Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer
    Wolf GT Head Neck 33 12 1666-1674 [2011]
  • Nivolumab in previously untreated melanoma without BRAF mutation
    Robert C N Engl J Med 372 (4) : 320 ~ 330 [2015]
  • Nivolumab in previously untreated melanoma without BRAF mutation
    Robert C N Engl J Med 372 4 320-330 [2015]
  • Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction
    Wang S J Exp Med 197 (9) : 1083 ~ 1091 [2003]
  • Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction
    Wang S J Exp Med 197 9 1083-1091 [2003]
  • Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors
    Riley JL Proc Natl Acad Sci U S A 99 (18) : 11790 ~ 11795 [2002]
  • Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors
    Riley JL Proc Natl Acad Sci U S A 99 18 11790-11795 [2002]
  • Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1
    Hirahara K Immunity 36 (6) : 1017 ~ 1030 [2012]
  • Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1
    Hirahara K Immunity 36 6 1017-1030 [2012]
  • Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer
    Bauman JE Cancer 120 (5) : 624 ~ 632 [2014]
  • Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer
    Bauman JE Cancer 120 5 624-632 [2014]
  • Infiltration of tumor-associated macrophages in human oral squamous cell carcinoma
    Li C Oncol Rep 9 (6) : 1219 ~ 1223 [2002]
  • Infiltration of tumor-associated macrophages in human oral squamous cell carcinoma
    Li C Oncol Rep 9 6 1219-1223 [2002]
  • Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen
    Berinstein NL Cancer Immunol Immunother 61 (6) : 771 ~ 782 [2012]
  • Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen
    Berinstein NL Cancer Immunol Immunother 61 6 771-782 [2012]
  • Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx
    De Stefani A Cancer 95 (1) : 90 ~ 97 [2002]
  • Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx
    De Stefani A Cancer 95 1 90-97 [2002]
  • Improved survival with ipilimumab in patients with metastatic melanoma
    Hodi FS N Engl J Med 363 (8) : 711 ~ 723 [2010]
  • Improved survival with ipilimumab in patients with metastatic melanoma
    Hodi FS N Engl J Med 363 8 711-723 [2010]
  • Immunotherapy in head and neck cancer: current practice and future possibilities
    Agada FO J Laryngol Otol 123 (1) : 19 ~ 28 [2009]
  • Immunotherapy in head and neck cancer: current practice and future possibilities
    Agada FO J Laryngol Otol 123 1 19-28 [2009]
  • Immunologic correlates of the abscopal effect in a patient with melanoma
    Postow MA N Engl J Med 366 (10) : 925 ~ 931 [2012]
  • Immunologic correlates of the abscopal effect in a patient with melanoma
    Postow MA N Engl J Med 366 10 925-931 [2012]
  • Immunobiology of head and neck cancer
    Whiteside TL Cancer Metastasis Rev 24 (1) : 95 ~ 105 [2005]
  • Immunobiology of head and neck cancer
    Whiteside TL Cancer Metastasis Rev 24 1 95-105 [2005]
  • Immune checkpoint blockade
    Naidoo J Hematol Oncol Clin North Am 28 (3) : 585 ~ 600 [2014]
  • Immune checkpoint blockade
    Naidoo J Hematol Oncol Clin North Am 28 3 585-600 [2014]
  • Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease
    Kuss I Adv Otorhinolaryngol 62 : 161 ~ 172 [2005]
  • Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease
    Kuss I Adv Otorhinolaryngol 62 161-172 [2005]
  • IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro
    Egan JE J Immunother 30 (6) : 624 ~ 633 [2007]
  • IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro
    Egan JE J Immunother 30 6 624-633 [2007]
  • Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences
    Grandis JR Clin Cancer Res 6 (7) : 2794 ~ 2802 [2000]
  • Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences
    Grandis JR Clin Cancer Res 6 7 2794-2802 [2000]
  • Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
    Linsley PS Immunity 1 (9) : 793 ~ 801 [1994]
  • Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
    Linsley PS Immunity 1 9 793-801 [1994]
  • High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
    Mu CY Med Oncol 28 (3) : 682 ~ 688 [2011]
  • High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
    Mu CY Med Oncol 28 3 682-688 [2011]
  • Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression
    Qin H Mol Ther 4 (6) : 551 ~ 558 [2001]
  • Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression
    Qin H Mol Ther 4 6 551-558 [2001]
  • Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody
    Dewan MZ Clin Cancer Res 15 (17) : 5379 ~ 5388 [2009]
  • Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody
    Dewan MZ Clin Cancer Res 15 17 5379-5388 [2009]
  • Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma
    Ian-James Malm Head & Neck 37 (8) : 1088 ~ 1095 [2015]
  • Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma
    Ian-James Malm Head & Neck 37 8 1088-1095 [2015]
  • Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck
    Whiteside TL Cancer Res 53 (23) : 5654 ~ 5662 [1993]
  • Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck
    Whiteside TL Cancer Res 53 23 5654-5662 [1993]
  • Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma
    Lyford-Pike S Cancer Res 73 (6) : 1733 ~ 1741 [2013]
  • Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma
    Lyford-Pike S Cancer Res 73 6 1733-1741 [2013]
  • Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib
    Schroeder CP Cancer Biol Ther 3 (9) : 847 ~ 852 [2004]
  • Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib
    Schroeder CP Cancer Biol Ther 3 9 847-852 [2004]
  • Checkpoint blocking antibodies in cancer immunotherapy
    Kyi C FEBS Lett 588 (2) : 368 ~ 376 [2014]
  • Checkpoint blocking antibodies in cancer immunotherapy
    Kyi C FEBS Lett 588 2 368-376 [2014]
  • Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer
    Schaefer C Br J Cancer 92 (5) : 913 ~ 920 [2005]
  • Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer
    Schaefer C Br J Cancer 92 5 913-920 [2005]
  • CTLA-4 is a second receptor for the B cell activation antigen B7
    Ledbetter JA Linsley PS J Exp Med 174 (3) : 561 ~ 569 [1991]
  • CTLA-4 is a second receptor for the B cell activation antigen B7
    Linsley PS J Exp Med 174 3 561-569 [1991]
  • CTLA-4 engagement inhibits IL-2accumulation and cell cycle progression upon activation of resting T cells
    Krummel MF J Exp Med 183 (6) : 2533 ~ 2540 [1996]
  • CTLA-4 engagement inhibits IL-2accumulation and cell cycle progression upon activation of resting T cells
    Krummel MF J Exp Med 183 6 2533-2540 [1996]
  • CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma
    Prieto PA Clin Cancer Res 18 (7) : 203 ~ 247 [2012]
  • CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma
    Prieto PA Clin Cancer Res 18 7 203-247 [2012]
  • B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
    Konishi J Clin Cancer Res 10 (15) : 5094 ~ 5100 [2004]
  • B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
    Konishi J Clin Cancer Res 10 15 5094-5100 [2004]
  • Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
    Taube JM Clin Cancer Res 20 (19) : 5064 ~ 5074 [2014]
  • Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
    Taube JM Clin Cancer Res 20 19 5064-5074 [2014]
  • A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1mediates suppression in the tumor microenvironment
    Strauss L Clin Cancer Res 13 (15 Pt 1) : 4345 ~ 4354 [2007]
  • A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1mediates suppression in the tumor microenvironment
    Strauss L Clin Cancer Res 13 15 Pt 1 4345-4354 [2007]